Business Wire

PA-WESTINGHOUSE-ELECTRIC

22.2.2024 10:01:28 CET | Business Wire | Press release

Share
Westinghouse Organizes VVER Fuel Forum with Customers

Westinghouse organized the 5th annual VVER Fuel Forum in Bratislava with representatives from six utilities. The forum, hosted by Slovenské elektrárne, provided the opportunity to share experiences and best practices with VVER-1000 and VVER-440 fuel deployment in operating reactors.

Westinghouse offered detailed briefings on fuel licensing, NOVA E-6 design enhancements, fabrication plant upgrades, delivery and operations.

As the leader of the European Union-funded APIS project (Accelerated Program for Implementation of secure VVER fuel Supply), Westinghouse also presented additional information on next-generation fuel design development and a harmonized approach for VVER fuel licensing.

“We are pleased to host so many colleagues in Bratislava to discuss the critical topic of fuel diversification,” said Branislav Strýček, Chairman of the Board of the Board of Directors and General Director of Slovenské elektrárne. “We are currently going through the preparation of the documentation in Slovakia for new VVER-440 fuel and expect to finish the licensing process by 2026-2027. We are looking forward to achieving diversification of fuel sources as we expand the lifetime operations of our nuclear plants.”

“In Ukraine, we started the licensing process for the Westinghouse VVER-440 fuel in 2022 and, thanks to great cooperation, we successfully completed it within 1.5 years. We received the first fuel load for Rivne unit 2 last September, ahead of the originally planned schedule. Our two units will be operating later this year with the new fuel, which has been performing well after six months," said Olexandr Depenchuk, Director for Nuclear and Radiation Safety of Energoatom. “The joint efforts of Energoatom and Westinghouse have enabled us to end our dependence on Russian fuel.”

“We recommend expediting the ongoing fuel diversification efforts in the context of the REPowerEU Plan launched in May 2022 and the global energy disruption caused by Russia’s invasion of Ukraine,” said Stefano Ciccarello, Acting Director General of the Euratom Supply Agency.

In Finland, Fortum is pursuing mechanical operating experiences with the new fuel type, after a test assembly manufactured by Westinghouse was loaded into the Loviisa-2 reactor last year. “The changes done in the design of the VVER-440 fuel we originally used in Loviisa in the early 2000s improved the fuel behavior and performance. We are currently reviewing the licensing and manufacturing documentation of the first new fuel deliveries and expect this work to be ready this summer,” said Iiro-Ville Lehtinen, Fortum Project Manager.

“Westinghouse will deliver the first batch of VVER-440 fuel assemblies to the Dukovany nuclear power plant at the end of this year. The deliveries for Temelín will follow a few months after Dukovany, as mutually agreed based on the refueling schedule,” said Rostislav Štaubr, Head of Nuclear Fuel Procurement of CEZ.

“We really appreciate our collaboration with Westinghouse,” said Svilena Nikolova, Head of Legal and Commercial Department of Kozloduy Nuclear Power Plant. “The diversification that has been obtained in terms of nuclear fuel supply is of great importance for the power plant. As Kozloduy celebrates its 50th anniversary this year, we will also receive the first load of new VVER-1000 fuel from Westinghouse for our unit 5.”

“We are delighted to share the achievements of this key program to ensure energy security and supply diversification for our customers in the region,” said Tarik Choho, Westinghouse President of Nuclear Fuel. “There were many great achievements in the past years and still a lot of work ahead of us. As the only European VVER fuel manufacturer, we are committed to delivering what is required by our customers.”

Westinghouse is a leading supplier of nuclear fuel, providing a uniquely diversified portfolio in the industry across nuclear reactor types, including PWR, BWR, AGR and VVER. Through our world-class manufacturing facilities in Sweden, the U.K. and the U.S., we focus on delivering innovative fuel technologies to meet our customers’ needs for lower fuel cycle costs, increased operational flexibility and efficiency, diversity of supply and accident-tolerant products. Learn more about our advanced fuel capabilities and how they relate to different reactors around the world: Westinghouse Nuclear > Nuclear Fuel.

Westinghouse Electric Company is shaping the future of carbon-free energy by providing safe, innovative nuclear technologies to utilities globally. Westinghouse supplied the world’s first commercial pressurized water reactor in 1957 and the company’s technology is the basis for nearly one-half of the world's operating nuclear plants. Over 135 years of innovation make Westinghouse the preferred partner for advanced technologies covering the complete nuclear energy life cycle. For more information, visit www.westinghousenuclear.com and follow us on Facebook, LinkedIn and X.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222283969/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye